Analysis of Under-Diagnosed Malignancy during Fine Needle Aspiration Cytology of Lymphadenopathies

Fine needle aspiration cytology (FNAC) is a useful tool in the evaluation of lymphadenopathy. It is a safe and minimally invasive procedure that provides preoperative details for subsequent treatment. It can also diagnose the majority of malignant tumors. However, there are some instances where the...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-08, Vol.24 (15), p.12394
Main Authors: Lee, Jeeyong, Ha, Hwa Jeong, Kim, Da Yeon, Koh, Jae Soo, Kim, Eun Ju
Format: Article
Language:English
Subjects:
biomarker
Biomarkers
Biopsy
Cancer
Candidates
Cellular biology
Datasets
Diagnosis
Disease
DNA microarrays
fine needle aspiration cytology (FNAC)
Gene expression
Genes
Genomics
lymphadenopathy
Lymphoma
malignancy
Metastasis
Motility
Non-Hodgkin's lymphomas
Patients
Proteins
RNA sequencing
Tumors
under-diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fine needle aspiration cytology (FNAC) is a useful tool in the evaluation of lymphadenopathy. It is a safe and minimally invasive procedure that provides preoperative details for subsequent treatment. It can also diagnose the majority of malignant tumors. However, there are some instances where the diagnosis of tumors remains obscure. To address this, we re-analyzed the misinterpreted patients' samples using mRNA sequencing technology and then identified the characteristics of non-Hodgkin's lymphoma that tend to be under-diagnosed. To decipher the involved genes and pathways, we used bioinformatic and biological analysis approaches, identifying the response to oxygen species, inositol phosphate metabolic processes, and peroxisome and PPAR pathways as possibly being involved with this type of tumor. Notably, these analyses identified FOS, ENDOG, and PRKAR2B as hub genes. cBioPortal, a multidimensional cancer genomics database, also confirmed that these genes were associated with lymphoma patients. These results thus point to candidate genes that could be used as biomarkers to minimize the false-negative rate of FNAC diagnosis. We are currently pursuing the development of a gene chip to improve the diagnosis of lymphadenopathy patients with the ultimate goal of improving their prognosis.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241512394